{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:47:21Z","timestamp":1793310441043,"version":"4.5.0"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T00:00:00Z","timestamp":1600732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["714312"],"award-info":[{"award-number":["714312"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006315","name":"ReumaNederland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006315","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1003296","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T17:23:15Z","timestamp":1600795395000},"page":"e1003296","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":93,"title":["Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7332-8072","authenticated-orcid":true,"given":"Xanthe M. E.","family":"Matthijssen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-3817","authenticated-orcid":true,"given":"Ellis","family":"Niemantsverdriet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom W. J.","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette H. M.","family":"van der Helm\u2013van Mil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,9,22]]},"reference":[{"issue":"2","key":"pmed.1003296.ref001","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2337\/diabetes.50.2.217","article-title":"The discovery of type 1 diabetes","volume":"50","author":"EAM Gale","year":"2001","journal-title":"Diabetes"},{"issue":"2","key":"pmed.1003296.ref002","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/ard.2009.126821","article-title":"A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis","volume":"70","author":"L Padyukov","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"pmed.1003296.ref003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.berh.2017.08.003","article-title":"Genetic and environmental risk factors for rheumatoid arthritis","volume":"31","author":"KD Deane","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"pmed.1003296.ref004","doi-asserted-by":"crossref","first-page":"R133","DOI":"10.1186\/ar2022","article-title":"Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides","volume":"8","author":"M Pedersen","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"pmed.1003296.ref005","doi-asserted-by":"crossref","first-page":"R949","DOI":"10.1186\/ar1767","article-title":"Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis","volume":"7","author":"AH van der Helm-van Mil","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"pmed.1003296.ref006","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1471-2474-11-187","article-title":"The relationship between the presence of anti-cyclic citrullinated peptide antibodies and clinical phenotype in very early rheumatoid arthritis","volume":"11","author":"MZ Cader","year":"2010","journal-title":"BMC Musculoskelet Disord"},{"issue":"8","key":"pmed.1003296.ref007","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.3899\/jrheum.121438","article-title":"Should we redefine treatment targets in rheumatoid arthritis? Low disease activity is sufficiently strict for patients who are anticitrullinated protein antibody-negative","volume":"40","author":"YM de Punder","year":"2013","journal-title":"J Rheumatol"},{"issue":"1","key":"pmed.1003296.ref008","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/art.23148","article-title":"Differences in synovial tissue infiltrates between anti-cyclic citrullinated peptide-positive rheumatoid arthritis and anti\u2013cyclic citrullinated peptide-negative rheumatoid arthritis","volume":"58","author":"M van Oosterhout","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"6","key":"pmed.1003296.ref009","doi-asserted-by":"crossref","first-page":"R182","DOI":"10.1186\/ar4372","article-title":"Differences in synovial fluid cytokine levels but not in synovial tissue cell infiltrate between anti-citrullinated peptide\/protein antibody-positive and -negative rheumatoid arthritis patients","volume":"15","author":"JA Gomez-Puerta","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"pmed.1003296.ref010","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/annrheumdis-2011-200379","article-title":"The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study","volume":"71","author":"M van den Broek","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"pmed.1003296.ref011","first-page":"500","article-title":"Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies","volume":"29","author":"A Mustila","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"pmed.1003296.ref012","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/ar4439","article-title":"ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial","volume":"16","author":"SD Seegobin","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"pmed.1003296.ref013","doi-asserted-by":"crossref","first-page":"e005246","DOI":"10.1136\/bmjopen-2014-005246","article-title":"Rheumatoid factor and anti-CCP do not predict progressive joint damage in patients with early rheumatoid arthritis treated with prednisolone: a randomised study","volume":"4","author":"I Hafstrom","year":"2014","journal-title":"BMJ Open"},{"issue":"1","key":"pmed.1003296.ref014","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/rheumatology\/keq230","article-title":"Predicting arthritis outcomes\u2014what can be learned from the Leiden Early Arthritis Clinic?","volume":"50","author":"DP de Rooy","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"pmed.1003296.ref015","volume-title":"NHG-Standaard: Artritis","author":"Nederlands Huisartsen Genootschap","year":"2017"},{"issue":"2","key":"pmed.1003296.ref016","doi-asserted-by":"crossref","first-page":"e000752","DOI":"10.1136\/rmdopen-2018-000752","article-title":"Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR\/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial","volume":"4","author":"LB Nordberg","year":"2018","journal-title":"RMD Open"},{"issue":"2","key":"pmed.1003296.ref017","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/annrheumdis-2016-209629","article-title":"What is rheumatoid arthritis? Considering consequences of changed classification criteria","volume":"76","author":"AH van der Helm-van Mil","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"pmed.1003296.ref018","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1136\/annrheumdis-2018-214868","article-title":"van der Helm-van Mil A. Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status","volume":"78","author":"DM Boeters","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"pmed.1003296.ref019","unstructured":"StatLine. [Persons moving between municipalities.] The Hague: Statistics Netherlands; 2017 [cited 2019 Mar 13]. Available from: https:\/\/statline.cbs.nl\/Statweb\/publication\/?DM=SLNL&PA=81734NED&D1=0&D2=0,41&D3=0,41&D4=l&VW=T."},{"issue":"1","key":"pmed.1003296.ref020","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/annrheumdis-2015-208870","article-title":"The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor","volume":"76","author":"S Ajeganova","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"pmed.1003296.ref021","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/rheumatology\/kew198","article-title":"Autoantibodies to two novel peptides in seronegative and early rheumatoid arthritis","volume":"55","author":"LM De Winter","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"pmed.1003296.ref022","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/art.23188","article-title":"Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides","volume":"58","author":"L Mathsson","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"3","key":"pmed.1003296.ref023","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/ar93","article-title":"Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset","volume":"2","author":"R Goldbach-Mansky","year":"2000","journal-title":"Arthritis Res"},{"issue":"8","key":"pmed.1003296.ref024","doi-asserted-by":"crossref","first-page":"699","DOI":"10.7326\/0003-4819-124-8-199604150-00001","article-title":"The effectiveness of early treatment with \u201csecond-line\u201d antirheumatic drugs. A randomized, controlled trial","volume":"124","author":"A van der Heide","year":"1996","journal-title":"Ann Intern Med"},{"issue":"7","key":"pmed.1003296.ref025","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7","article-title":"Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study","volume":"44","author":"AE van Ede","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"11","key":"pmed.1003296.ref026","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial","volume":"52","author":"YP Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"12","key":"pmed.1003296.ref027","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1002\/art.27692","article-title":"Long-term impact of delay in assessment of patients with early arthritis","volume":"62","author":"MP van der Linden","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"8","key":"pmed.1003296.ref028","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2012-202289","article-title":"Improved early identification of arthritis: evaluating the efficacy of Early Arthritis Recognition Clinics","volume":"72","author":"JA van Nies","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"pmed.1003296.ref029","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1136\/annrheumdis-2013-204867","article-title":"Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry","volume":"74","author":"J Sorensen","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"pmed.1003296.ref030","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"JS Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"pmed.1003296.ref031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"JA Singh","year":"2016","journal-title":"Arthritis Care Res"},{"issue":"9194","key":"pmed.1003296.ref032","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"R Maini","year":"1999","journal-title":"Lancet"},{"issue":"6","key":"pmed.1003296.ref033","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/1756-185X.12695","article-title":"Comparison of the DAS28-CRP and DAS28-ESR in patients with rheumatoid arthritis.","volume":"18","author":"I Sengul","year":"2015","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"pmed.1003296.ref034","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1002\/art.24661","article-title":"Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts","volume":"60","author":"D van der Woude","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"5","key":"pmed.1003296.ref035","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/annrheumdis-2014-207080","article-title":"van der Helm-van Mil AH. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms","volume":"75","author":"S Ajeganova","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"pmed.1003296.ref036","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/annrheumdis-2016-209835","article-title":"The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission","volume":"76","author":"LH van Tuyl","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"pmed.1003296.ref037","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1477-7525-1-20","article-title":"The Stanford Health Assessment Questionnaire: dimensions and practical applications","volume":"1","author":"B Bruce","year":"2003","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"pmed.1003296.ref038","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M","article-title":"Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis","volume":"43","author":"M Kosinski","year":"2000","journal-title":"Arthritis Rheum"},{"key":"pmed.1003296.ref039","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1136\/annrheumdis-2018-214618","article-title":"Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up","volume":"78","author":"PB Poppelaars","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"pmed.1003296.ref040","article-title":"van der Helm-van Mil AH. Early intensive treatment normalises excess mortality in ACPA-negative RA but not in ACPA-positive RA","author":"XM Matthijssen","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"pmed.1003296.ref041","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/acr.23497","article-title":"Is anti-citrullinated protein antibody-positive rheumatoid arthritis still a more severe disease than anti-citrullinated protein antibody-negative rheumatoid arthritis? A longitudinal cohort study in rheumatoid arthritis patients diagnosed from 2000 onward","volume":"70","author":"AC Boer","year":"2018","journal-title":"Arthritis Care Res"},{"issue":"5","key":"pmed.1003296.ref042","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10067-017-3962-5","article-title":"Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice","volume":"37","author":"GA Versteeg","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"6","key":"pmed.1003296.ref043","first-page":"848","article-title":"Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register","volume":"77","author":"JM Gwinnutt","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"pmed.1003296.ref044","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K","article-title":"van Riel PLCM. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts","volume":"41","author":"AM van Gestel","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"3","key":"pmed.1003296.ref045","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrrheum.2012.237","article-title":"Genetics and epigenetics of rheumatoid arthritis","volume":"9","author":"S Viatte","year":"2013","journal-title":"Nature Rev Rheumatol"},{"issue":"6","key":"pmed.1003296.ref046","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/annrheumdis-2018-214539","article-title":"Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients","volume":"78","author":"F Humby","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T17:23:53Z","timestamp":1600795433000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003296"}},"subtitle":[],"editor":[{"given":"Carlomaurizio","family":"Montecucco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,9,22]]},"references-count":46,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1003296","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,22]]}}}